Research
Search
Close
HU Haiyan
- Chief Physician, Doctoral Supervisor
- Department: Oncology
- Research Area: Oncology
- Research Interests: Tumour immunity, function of non-coding RNA
- Contact: xuri1104@163.com
- Fellowship, Department of Breast Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 2011
- MD from Jinan University of Medical Science, 2005
- MM from Henan Medical School of Zhengzhou University, 2002
- BM from Southeast University School of Medicine, 1997
- Vice Director, Department of Clinical Research Ward, Shanghai Sixth People's Hospital
- Vice Chairman, Youth Committee of Molecular Diagnosis, Shanghai Medical Association
- Director, Clinical Research Technology Centre, Institute of Molecular Diagnostic Innovative Technology, Shanghai Research Institute of Experimental Medicine
- Secretary, Study Group of Bone and Soft Tissue Sarcoma in Tumour Branch of Shanghai Medical Association Committee Member, Shanghai Bone Tumour Branch of China Tumour Control Union Executive Member, China Computer Society
- Committee Member, Medical-Industrial Integration Branch of China Pharmaceutical Association Secretary, Shanghai Sarcoma Clinical Center
- Vice Director, Minor Nucleic Acid Drug Development Engineering Center, Guangdong Province
- Zhai C, Xie F, Xu J#. Correlation between membrane proteins and sizes of extracellular vesicles and particles: A potential signature for cancer diagnosis, Journal of Extracellular Vesicles, 2023, doi: 10.1002/jev2.12391.
- Zhou Y, Li M, Zhang B#. A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas, BMC Medicine, 2023, doi: 10.1186/s12916-023-03132-x.
- Ding X, Liu Y, Zhang Y#. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study, Anti-Cancer Drugs, 2023, doi: 10.1097/CAD.0000000000001482.
- Huang G, Yin Z, Wang X#. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells, Phytomedicine, 2023, doi: 10.1016/j.phymed.2023.154918.
- Su R, Li C, Wang X#. PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration, Molecular Therapy Nucleic Acids, 2023, doi: 10.1016/j.omtn.2023.04.026.
- Ma H, Wang X, Zhao J#. The heterogeneity and drug resistance of malignant cells and intercellular communication of microenvironment in osteosarcoma: Based on single-cell analysis, Clinical and Translational Discovery, 2023, doi: 10.1002/ctd2.202.
- Zhou Y, Yang Q, Dong Y#. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001, Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, doi: 10.1158/1078-0432.CCR-22-2470.
- Zhang F, Sun J, Tang X#. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML, Cell Death and Disease, 2022, doi: 10.1038/s41419-022-05023-0.
- Zhang Z, Ji W, Huang J#. Characterization of the tumour microenvironment phenotypes in malignant tissues and pleural effusion from advanced osteoblastic osteosarcoma patients, Clin Transl Med, 2022, doi: 10.1002/ctm2.1072.
- Zhou Y, Yang D, Yang Q#. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma, Nature Communications, 2020, doi: 10.1038/s41467-020-20059-6.
- [Fei Jia, Hu Haiyan, etc.] (2015), “Antisense oligonucleotides targeting microRNA-21 seed sequences and applications”, ZL201310304132.9
- [Hu Haiyan, Yao Yang, etc.] (2019), “Bone and Soft Tissue Sarcoma Clinical Trials and Follow-up Database Software V1.0”, 200R0210512
- [Hu Haiyan, Zhou Yan, etc.] (2021), “Bone Primary and Secondary Tumours HxeerAI Cloud Artificial Intelligence Cloud Computing Platform V1.0”, 2021SR1280778
